Form 4: Liquidia CHRO Sells Shares for Tax Obligations

Liquidia Corp's Chief Human Resource Officer, Sarah Krepp, sold 13,165 shares of common stock for $37.43 per share to cover tax obligations following the vesting of performance and restricted stock units.

Summary

• Sarah Krepp, Chief Human Resource Officer of Liquidia Corp, reported transactions involving company common stock.
• On January 9, 2026, 12,716 Performance Stock Units (PSUs) converted into common stock on a one-for-one basis. These PSUs were part of a grant of 50,861 PSUs on January 11, 2025, with 25% vesting on January 11, 2026.
• Following this conversion, Krepp's beneficial ownership of common stock was 153,934 shares.
• On January 12, 2026, Krepp sold 13,165 shares of common stock at a price of $37.43 per share.
• The sale was executed under a Rule 10b5-1 plan adopted on December 15, 2023, and was specifically to cover tax obligations arising from the settlement of vested RSUs and PSUs.
• After these transactions, Krepp's direct beneficial ownership of common stock is 140,769 shares, and she holds 38,145 unvested PSUs.
• Her total beneficial ownership of common stock includes 29,482 unvested RSUs from a January 11, 2024 grant, 7,787 unvested RSUs from a July 1, 2024 grant, 38,145 unvested RSUs (PSUs) from a January 11, 2025 grant, 25,000 unvested RSUs from a July 1, 2025 grant, and 5,312 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The filing is a neutral, routine disclosure of an executive's stock transaction for tax purposes, neither indicating positive nor negative company performance or outlook.

Positives

• The sale was pre-planned under a Rule 10b5-1 plan, indicating a structured approach to managing stock holdings rather than an immediate reaction to market conditions.
• The sale was specifically to cover tax obligations related to vested equity, which is a common and expected event for executives receiving equity compensation.

Negatives

• A significant number of shares (13,165) were sold by a key executive, which could be perceived negatively by some investors, even if for tax purposes.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance, focusing solely on executive stock transactions.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity, specifically an executive's sale of shares to cover tax liabilities from vested equity. Such transactions are common across all industries for executives receiving stock-based compensation and do not inherently reflect on broader industry trends or competitive positioning.

Comparison to Industry Standards

• The transaction is a standard practice for executives to manage tax obligations arising from equity compensation. It aligns with typical insider trading disclosures seen in publicly traded companies across various sectors, particularly in the biotechnology or pharmaceutical industry where equity compensation is prevalent.
• No specific comparable companies or projects are mentioned in this filing to allow for a direct comparative assessment of results.

Stakeholder Impact

• Shareholders: The sale represents a minor dilution of the executive's direct ownership but is a routine event for tax purposes. The pre-planned nature (10b5-1) suggests no immediate negative sentiment from the executive.
• Employees: The vesting of PSUs and RSUs indicates the ongoing compensation structure for executives, which can be a positive signal for employee retention and motivation.

Next Steps

• Remaining PSUs granted on January 11, 2025, will vest ratably on a quarterly basis over three years after January 11, 2026.
• Remaining unvested RSUs from various grants will vest according to their respective schedules.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where an executive sold shares to cover tax liabilities from vested equity awards, executed under a pre-arranged 10b5-1 plan. Such a transaction is not indicative of the company's fundamental performance or future prospects and therefore does not warrant a change in investment recommendation based solely on this filing. Investors should continue to hold and evaluate the company based on its financial results, strategic developments, and market conditions.

Keywords

Liquidia Corp, LQDA, Form 4, Insider Trading, Stock Sale, Executive Compensation, Sarah Krepp, Rule 10b5-1, Performance Stock Units, Restricted Stock Units, Tax Obligations